Quantum Materials (QTMM) 10-Q 13 May 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2016	May. 10, 2016
Document And Entity Information
Entity Registrant Name	QUANTUM MATERIALS CORP.
Entity Central Index Key	1,403,570
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		324,063,789
Trading Symbol	QTMM
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Jun. 30, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 8,960	$ 673,839
Restricted cash		65,330
Prepaid expenses and other current assets	$ 172,171	258,391
TOTAL CURRENT ASSETS	181,131	997,560
PROPERTY AND EQUIPMENT, net of accumulated depreciation of $127,468 and $63,615	759,645	776,039
LICENSES AND PATENTS, net of accumulated amortization of $65,618 and $36,707	127,125	156,036
TOTAL ASSETS	1,067,901	1,929,635
CURRENT LIABILITIES
Accounts payable and accrued expenses	635,111	364,797
Accrued salaries	294,267	$ 577,027
Notes payable	170,024
Current portion of convertible debentures, net of unamortized discount	362,915
TOTAL CURRENT LIABILITIES	1,462,317	$ 941,824
CONVERTIBLE DEBENTURES, net of current portion and unamortized discount	25,050	258,838
TOTAL LIABILITIES	$ 1,487,367	$ 1,200,662
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' (DEFICIT) EQUITY
Common stock, $.001 par value, authorized 400,000,000 shares, 323,388,331 and 307,097,420 issued and outstanding at March 31, 2016 and June 30, 2015, respectively	$ 323,388	$ 307,097
Additional paid-in capital	27,073,414	24,099,177
Accumulated deficit	(27,816,268)	(23,677,301)
TOTAL STOCKHOLDERS' (DEFICIT) EQUITY	(419,466)	728,973
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 1,067,901	$ 1,929,635

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Statement of Financial Position [Abstract]
Property and equipment, accumulated depreciation	$ 127,468	$ 63,615
Licenses and patents, accumulated amortization	$ 65,618	$ 36,707
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	400,000,000	400,000,000
Common stock, issued	323,388,331	307,097,420
Common stock, outstanding	323,388,331	307,097,420

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
REVENUES	$ 225,000		$ 225,000
OPERATING EXPENSES
General and administrative	903,795	$ 808,209	4,212,120	$ 2,550,972
Research and development	19,210	12,571	165,265	60,233
TOTAL OPERATING EXPENSES	923,005	820,780	4,377,385	2,611,205
LOSS FROM OPERATIONS	$ (698,005)	(820,780)	$ (4,152,385)	(2,611,205)
OTHER (INCOME) EXPENSE
Change in fair value of derivative liabilities		$ 0		(1,871,337)
Gain on settlement			$ (174,568)	(546,129)
Beneficial conversion expense		$ 197,728		428,037
Interest expense, net	$ 10,452	21,838	$ 32,023	47,674
Accretion of debt discount	43,903	92,323	129,127	310,733
TOTAL OTHER (INCOME) EXPENSE	54,355	311,889	(13,418)	(1,631,022)
NET LOSS	$ (752,360)	$ (1,132,669)	$ (4,138,967)	$ (980,183)
LOSS PER COMMON SHARE
Basic and diluted	$ 0	$ 0	$ (0.01)	$ 0
WEIGHTED AVERAGE SHARES OUTSTANDING
Basic and diluted	322,675,999	281,526,245	316,418,240	269,903,313

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity (Unaudited) - 9 months ended Mar. 31, 2016 - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balances beginning at Jun. 30, 2015	$ 307,097	$ 24,099,177	$ (23,677,301)	$ 728,973
Balances beginning, shares at Jun. 30, 2015	307,097,420
Common stock issued for cash	$ 1,000	99,000		100,000
Common stock issued for cash, shares	1,000,000
Common stock issued for warrant and option exercises	$ 12,279	387,398		399,677
Common stock issued for warrant and option exercises, shares	12,279,211
Common stock issued for services	$ 2,900	287,100		290,000
Common stock issued for services, shares	2,900,000
Cancellation of shares	$ (638)	(252,930)		(253,568)
Cancellation of shares, shares	(638,300)
Stock warrants issued in exchange for accrued salaries		821,979		821,979
Stock-based compensation	$ 750	$ 1,631,690		1,632,440
Stock-based compensation, shares	750,000
Net loss			$ (4,138,967)	(4,138,967)
Balances beginning at Mar. 31, 2016	$ 323,388	$ 27,073,414	$ (27,816,268)	$ (419,466)
Balances beginning, shares at Mar. 31, 2016	323,388,331

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,138,967)	$ (980,183)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	92,764	48,368
Stock-based compensation	2,080,892	$ 149,014
Stock issued for services	$ 158,345
Stock options issued for services		$ 642,116
Stock issued for interest		40,568
Gain on settlement	$ (174,568)	(546,129)
Beneficial conversion feature		428,037
Change in fair value of derivative liability		(1,871,337)
Accretion of debt discount	$ 129,127	$ 310,733
Effects of changes in operating assets and liabilities:
Prepaid expenses and other current assets	237,899
Accounts payable and accrued expenses	$ 321,258	$ (49,978)
Accrued salaries		86,528
NET CASH USED IN OPERATING ACTIVITIES	$ (1,293,250)	(1,742,263)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	$ (47,459)	(479,773)
Purchase of license and patents		(137,743)
Change in restricted cash investments	$ 65,330	1,063
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	17,871	(616,453)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock	$ 460,500	1,058,049
Proceeds from issuance of convertible debentures		1,200,050
Proceeds from issuance of note payable	$ 150,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	610,500	2,258,099
NET DECREASE IN CASH	(664,879)	(100,617)
CASH AND CASH EQUIVALENTS, beginning of period	673,839	120,501
CASH AND CASH EQUIVALENTS, end of period	$ 8,960	$ 19,884

Basis of Presentation

Basis of Presentation	9 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 1 – BASIS OF PRESENTATION General The accompanying consolidated financial statements include the accounts of Quantum Materials Corp. and its wholly owned subsidiary, Solterra Renewable Technologies, Inc. (collectively referred to as the “Company”). The consolidated financial statements of the Company as of and for the three and nine months ended March 31, 2016 are unaudited and have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2015. The year-end balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. In the opinion of management, the accompanying unaudited financial information includes all adjustments necessary for a fair presentation of the interim financial information. Operating results for the interim periods are not necessarily indicative of the results of any subsequent periods. Certain information in the footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted for the interim periods presented under the United States Securities and Exchange Commission (“SEC”) rules and regulations. As such, these interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended June 30, 2015. Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the classifications of the current year consolidated financial statements. Nature of Operations The Company is a nanotechnology company specializing in the design, development, production and supply of quantum dots, including tetrapod quantum dots, a high performance variant of quantum dots, and highly uniform nanoparticles, using its patented automated continuous flow production process. Quantum dots and other nanoparticles are expected to be increasingly utilized in a range of applications in the life sciences, television and display, solid state lighting, solar energy, battery, security ink, and sensor sectors of the market. Key uncertainties and risks to the Company include, but are not limited to, if and how quickly various industries adopt and fully embrace quantum dot technology and technological changes, including those developed by our competitors, rendering our technology uncompetitive or obsolete. Going Concern The Company recorded losses from continuing operations in the current period presented and has a history of losses. The ability of the Company to continue as a going concern is dependent upon its ability to reverse negative operating trends, obtain revenues from operations, raise additional capital, and/or obtain debt financing. In conjunction with anticipated revenue streams, management is currently negotiating equity and debt financing, the proceeds from which would be used to settle outstanding debts, to finance operations, and for general corporate purposes. However, there can be no assurance that the Company will be able to raise capital, obtain debt financing, or improve operating results sufficiently to continue as a going concern. The accompanying unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern. Restatement of Unaudited Quarterly Financial Data The Company identified certain errors in the Company’s previously released financial information for the quarters ended December 31, 2014 and March 31, 2015. As a result of the identification of the issues, various accounting corrections to the previously reported financial information were recorded and reported on Form 10-K/A filed with the Securities and Exchange Commission on February 2, 2016 and are incorporated by reference herein.

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 2 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: March 31, 2016 June 30, 2015 (unaudited) Furniture and fixtures $ 1,625 $ 1,625 Computers and software 11,447 11,447 Machinery and equipment 874,041 826,582 887,113 839,654 Less: accumulated depreciation 127,468 63,615 Total property and equipment, net $ 759,645 $ 776,039 Depreciation expense for the three months ended March 31, 2016 and 2015 was $21,853 and $8,354, respectively, and $63,853 and $24,048 for the nine months ended March 31, 2016 and 2015, respectively.

Licenses and Patents

Licenses and Patents	9 Months Ended
	Mar. 31, 2016
Finite-Lived Intangible Assets, Net [Abstract]
Licenses and Patents	NOTE 3 – LICENSES AND PATENTS Licenses and patents consisted of the following: March 31, 2016 June 30, 2015 (unaudited) William Marsh Rice University $ 40,000 $ 40,000 University of Arizona 15,000 15,000 Bayer acquired patents 137,743 137,743 192,743 192,743 Less: accumulated amortization 65,618 36,707 Total licenses and patents, net $ 127,125 $ 156,036 Amortization expense for the three months ended March 31, 2016 and 2015 was $9,637 and $9,637, respectively, and $28,911 and $24,320 for the nine months ended March 31, 2016 and 2015, respectively.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Value of Financial Instruments	NOTE 4 – FAIR VALUE OF FINANCIAL INSTRUMENTS The Company follows Financial Accounting Standards Board Accounting Standards Update (“ASU”) 2011-04 “Fair Value Measurement” This guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Hierarchical levels, as defined in this guidance and directly related to the amount of subjectivity associated with the inputs to fair valuations of these assets and liabilities are as follows: Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 – Inputs that are both significant to the fair value measurement and unobservable. The reported fair values for financial instruments that use Level 2 and Level 3 inputs to determine fair value are based on a variety of factors and assumptions. Accordingly, certain fair values may not represent actual values of the financial instruments that could have been realized as of March 31, 2016 and June 30, 2015 or that will be realized in the future and do not include expenses that could be incurred in an actual sale or settlement. The carrying amounts of cash and cash equivalents, accounts payable and current debt approximate their fair value due to the short maturity of those instruments. Convertible Debentures The Company measured the estimated fair value of the convertible debentures using significant other observable inputs, representative of a Level 2 fair value measurement, including the interest and conversion rates for the instruments. The following table sets forth the fair value of the Company’s convertible debentures as of March 31, 2016 and June 30, 2015: March 31, 2016 June 30, 2015 (unaudited) Carrying Fair Carrying Fair Amount Value Amount Value Convertible debentures issued September 18, 2014 $ 25,050 $ 18,370 $ 25,050 $ 31,730 Convertible debentures issued January 15, 2015 $ 500,000 $ 916,667 $ 500,000 $ 1,583,333 Derivative Liabilities The Company has evaluated the application of ASC 815, “ Derivatives and Hedging”, Level 3 Valuation Techniques Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 financial liabilities consist of the derivative liabilities for which there is no current market for these securities such that the determination of fair value requires significant judgment or estimation. At the date of the original transaction, the Company valued the convertible debenture that contains down round provisions using a lattice model, with the assistance of a valuation consultant, for which management understands the methodologies. This model incorporated transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as assumptions about future financings, volatility, and holder behavior. Using assumptions, consistent with the original valuation, the Company has subsequently used the Black-Scholes model for calculating the fair value. The Company is not a party to any hedge arrangements, commodity swap agreements or any other derivative financial instruments other than described above.

Convertible Debentures

Convertible Debentures	9 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Convertible Debentures	NOTE 5 – CONVERTIBLE DEBENTURES The following table sets forth activity associated with the convertible debentures: March 31, 2016 June 30, 2015 (unaudited) Convertible debentures issued November 4, 2008 $ - $ 500,000 Convertible debentures issued February 6, 2014 - 400,000 Convertible debentures issued September 18, 2014 25,050 500,050 Convertible debentures issued November 25, 2014 - 350,000 Convertible debentures issued January 15, 2015 500,000 500,000 525,050 2,250,050 Less: amount converted to shares - 1,725,000 Total convertible debentures outstanding 525,050 525,050 Less: unamortized discount 137,085 266,212 387,965 258,838 Less: current portion 362,915 - Total convertible debentures, net of current portion $ 25,050 $ 258,838 November 2008 Convertible Debenture On November 4, 2008, the Company entered into a Securities Purchase Agreement, Debenture, Security Agreement, Subsidiary Guarantee Agreement, Registration Rights Agreement, Escrow Agreement, Stock Pledge Agreement and other related transactional documents (the “Transaction Documents”) to obtain $1,500,000 in gross proceeds from three non-affiliated parties (collectively hereinafter referred to as the “Debenture Holders”) in exchange for 3,525,000 restricted shares of common stock of the Company (the “Restricted Shares”) and Debentures in the principal amount aggregating $1,500,000. Each Debenture originally had a term of three years maturing on November 4, 2011 bearing interest at the rate of 8% per annum and is pre-payable by the Company at any time without penalty, subject to the Debenture Holders’ conversion rights. Starting in 2011, the Company obtained one year extensions of the maturity date of the Debentures through November 4, 2014. In partial consideration of such a loan extension, the Company agreed to issue to the Debenture Holders warrants to purchase an aggregate of 2,000,000 shares of common stock exercisable at $0.10 per share. These warrants contain cashless exercise provisions in the event that there is no current registration statement filed. When the maturity date was extended in June 2013 to November 4, 2014, the conversion price per share was lowered to $0.06 per share. On June 30, 2014, $1,000,000 of the Debentures were converted into 16,666,667 common shares. The remaining $500,000 was converted at $0.06 per share into 8,333,333 of common shares at the due date November 4, 2014. The Company recorded the conversion at the fair market value of the shares at the date of conversion, off-set by the reduction of the derivative liability. Interest expense for the three months ended March 31, 2016 and 2015 was $0 and $0, respectively, and $0 and $21,805 for the nine months ended March 31, 2016 and 2015, respectively. As of March 31, 2016 and June 30, 2015, $0 of principal was outstanding. February 2014 Convertible Debenture On February 6, 2014, the Company entered into a Securities Purchase Agreement, Debenture and Escrow Agreement to obtain $400,000 in gross proceeds from two non-affiliated parties (collectively hereinafter referred to as the “Debenture Holders”). The Debentures have a term of two years maturing on January 31, 2016 and bear interest at the rate of 8% per annum. The Debentures are pre-payable by the Company at any time without penalty. The Debenture Holders have the right of conversion at a conversion price of $0.04 per share at any date. The Debenture Holders received 5,000,000 common stock warrants exercisable at $0.06 per share through December 31, 2016. The debt is secured by a security interest in certain microreactor equipment. Pursuant to the Securities Purchase Agreement, the investor has certain preferential rights to fund a second microreactor at a cost of up to $650,000. Such rights were exercised as described under the January 2015 Convertible Debenture below. In accounting for the above convertible debentures, the Company allocated the fair value of the warrants to the proceeds received in the amount of $95,603, recorded as debt discount. The debt discount is amortized using the effective interest rate method over the life of the loan, two years. The Company recognized accretion of debt discount expense for the three months ended March 31, 2016 and 2015 of $0 and $51,785, respectively, and $0 and $51,785 for the nine months ended March 31, 2016 and 2015, respectively. Interest expense for the three months ended March 31, 2016 and 2015 was $0 and $18,762, respectively, and $0 and $18,762 for the nine months ended March 31, 2016 and 2015, respectively. In January 2015, the holders of the $400,000 convertible debenture converted into 10,000,000 shares of common stock. As of March 31, 2016 and June 30, 2015, $0 of principal was outstanding. September 2014 Convertible Debenture Between September 16, 2014 and October 28, 2014, the Company entered into Convertible Debenture Agreements to obtain a total of $500,050 in gross proceeds from five non-affiliated parties (collectively hereinafter referred to as the “Debenture Holders”). The Debentures have terms of five years maturing between September 16, 2019 and October 30, 2019. The Debentures bear interest at the rate of 6% per annum and are pre-payable by the Company at any time without penalty. The Debenture Holders have the right of conversion at a conversion price of $0.15 per share at any date, and will receive an equal number of warrants having a strike price of $0.30 per share and a term of five years. In accounting for the above convertible debentures, the Company allocated the fair value of the warrants to the proceeds received in the amount of $203,074, recorded as debt discount. The debt discount is amortized using the effective interest rate method over the life of the loan, five years. The Company recognized accretion of debt discount expense for the three months ended March 31, 2016 and 2015 of $0 and $0, respectively, and $0 and $203,074 for the nine months ended March 31, 2016 and 2015, respectively. The Company recognized a beneficial conversion expense for the three months ended March 31, 2016 and 2015 of $0 and $0, respectively, and $0 and $230,309 for the nine months ended March 31, 2016 and 2015, respectively. Interest expense for the three months ended March 31, 2016 and 2015 was $380 and $0, respectively, and $1,148 and $4,073 for the nine months ended March 31, 2016 and 2015, respectively. In October 2014, $350,000 of the Debentures were converted into 2,333,333 shares of common stock and an equal number of warrants and in December 2014, $125,000 of the Debentures were converted into 833,334 shares of common stock and an equal number of warrants. As of March 31, 2016 and June 30, 2015, $25,050 of principal was outstanding. November 2014 Convertible Debenture On November 25, 2014, the Company entered into a Convertible Debenture Agreement which would allow the Company to borrow up to a total of $500,000 in gross proceeds from a non-affiliated party. The Debenture has a term of five years maturing on November 25, 2019 and bears interest at the rate of 6% per annum and is pre-payable by the Company at any time without penalty. The debenture holder funded five times between December 2014 and April 2015 for total proceeds to the Company of $350,000. The first three fundings of $50,000 each converted at $0.15 per share, and received an equal number of warrants having a strike price of $0.30 per share and a term of two years. The fourth funding of $50,000 and the fifth funding of $150,000 converted at $0.12 and $0.10 per share, respectively. In January 2015 $100,000 was converted into 666,667 of common stock and in April 2015 $250,000 was converted into 2,250,000 of common stock. The Company recognized a beneficial conversion expense for the three months ended March 31, 2016 and 2015 of $0 and $45,833, respectively, and $0 and $45,833 for the nine months ended March 31, 2016 and 2015, respectively. As of March 31, 2016 and June 30, 2015, $0 of principal was outstanding and on September 18, 2015, the Company notified the debenture holder that per the terms of the debenture, the debenture was deemed cancelled. January 2015 Convertible Debenture On January 15, 2015, the Company entered into Convertible Debenture Agreements to obtain $500,000 in gross proceeds from two non-affiliated parties (collectively hereinafter referred to as the “Debenture Holders”). The Debentures have a term of two years maturing on January 15, 2017 and bear interest at the rate of 8% per annum. The debentures are pre-payable by the Company at any time without penalty. The Debenture Holders have the right of conversion at a conversion price of $0.06 per share at any date. The Debenture Holders received 6,250,000 common stock warrants exercisable at $0.06 per share through January 15, 2017. The debt is secured by a security interest in certain microreactor equipment. The Agreement also provides for the investors to have the right to appoint one member to the Company’s Board of Directors in the event that any one of the aforementioned debentures are converted into common stock of the Company. In accounting for the convertible debentures, the Company allocated the fair value of the warrants to the proceeds received in the amount of $348,105, recorded as debt discount and is amortized using the effective interest rate method over the life of the loan, two years. The Company recognized accretion of debt discount expense for the three months ended March 31, 2016 and 2015 of $43,903 and $40,538, respectively, and $129,127 and $40,538 for the nine months ended March 31, 2016 and 2015, respectively. The Company recognized a beneficial conversion expense for the three months ended March 31, 2016 and 2015 of $0 and $151,895, respectively, and $0 and $151,895 for the nine months ended March 31, 2016 and 2015, respectively. Interest expense for the three months ended March 31, 2016 and 2015 was $9,973 and $0, respectively, and $30,137 and $0 for the nine months ended March 31, 2016 and 2015, respectively.

Notes Payable

Notes Payable	9 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Notes Payable	NOTE 6 – NOTES PAYABLE Promissory Note In February 2016 the Company issued an unsecured promissory note for $150,000 to a private individual at an interest rate of 0.5% per annum. The note is due May 5, 2016. Interest expense for the three months ended March 31, 2016 and 2015 was $100 and $0, respectively, and $100 and $0 for the nine months ended March 31, 2016 and 2015, respectively. On May 5, 2016, the note was paid in full. Note Payable – Insurance In March 2016, to finance an insurance premium, the Company issued a negotiable promissory note for $20,024 at an interest rate of 4.87% per annum. The note is due November 11, 2016. The balance outstanding at March 31, 2016 was $20,024.

Equity Transactions

Equity Transactions	9 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Equity Transactions	NOTE 7 – EQUITY TRANSACTIONS Common Stock During the nine months ended March 31, 2016, the Company issued 1,000,000 shares of common stock for cash proceeds of $100,000. Additionally, investors exercised options and warrants to purchase 12,279,211 shares of common stock for cash proceeds of $360,500 and forgiveness of a liability of the Company of $39,177. Included were cashless exercises of 3,325,000 options and 6,802,634 warrants that resulted in the issuance of 2,146,629 and 3,381,154 shares of common stock, respectively. During the nine months ended March 31, 2016, the Company granted 2,800,000 shares of common stock to consultants at the fair market value of $280,000. This was recognized as a prepaid asset and will be amortized to expense over the life of the agreement. Additionally, the Company granted 100,000 shares of common stock to employees and consultants at the fair market value of $10,000 and was recognized as general and administrative expense. During the nine months ended March 31, 2016, the Company cancelled 638,300 shares of common stock. See Note 14. Stock Warrants A summary of activity of the Company’s stock warrants for the nine months ended March 31, 2016 is presented below: Weighted Weighted Average Weighted Average Remaining Average Exercise Number of Contractual Grant Date Price Warrants Term in Years Fair Value Balance as of June 30, 2015 $ 0.09 48,284,833 $ 0.13 Expired 0.07 (7,895,833 ) 0.08 Granted 0.06 9,048,508 0.13 Exercised 0.07 (13,554,062 ) 0.09 Cancelled 0.24 (416,667 ) 0.14 Balance as of March 31, 2016 $ 0.09 35,466,779 1.32 $ 0.15 Vested and exercisable as of March 31, 2016 $ 0.09 35,466,779 1.32 $ 0.15 During the nine months ended March 31, 2016, 6,802,634 warrants were exercised in cashless transactions that resulted in the issuance of 3,381,154 shares of common stock. In November 2015, certain officers and employees converted accrued salaries of $409,667 into 6,827,778 warrants to purchase the Company’s common stock. The warrants are exercisable at $0.06 per share for a period of two years. The fair value of the stock warrants at the time of conversion was $821,979. The variance of $412,312 was recognized as stock-based compensation in general and administrative expense. Outstanding warrants at March 31, 2016 expire during the period May 2016 to November 2019 and have exercise prices ranging from $0.04 to $0.30.

Stock-Based Compensation.

Stock-Based Compensation.	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation.	NOTE 8 – STOCK-BASED COMPENSATION The Company follows ASC 718 “Compensation — Stock Compensation” In October 2009 the Board of Directors authorized the approval of a stock option plan covering 7,500,000 shares of common stock, which was increased to 10,000,000 shares in December 2009 and approved by stockholders in January 2010. The Plan provides for the direct issuance of common stock and the grant of incentive and non-incentive stock options. As of March 31, 2016, 9,200,000 options have been granted, with terms ranging from five to ten years, and 250,000 have been cancelled. In March 2012 3,500,000 stock options, with a term of five years, were granted outside of a stock option plan. In January 2013 the Board of Directors authorized the approval of a stock option plan covering 20,000,000 shares of common stock, which was increased to 60,000,000 shares in March 2013 and approved by stockholders in March 2013. The Plan provides for the direct issuance of common stock and the grant of incentive and non-incentive stock options. As of March 31, 2016, 68,203,473 options have been granted, with terms ranging from five to ten years, 3,325,000 have been exercised and 12,703,225 have been cancelled. On February 17, 2016, the Shareholders approved the 2015 Employee Benefit and Consulting Services Compensation Plan covering 15,000,000 shares. The Plan provides for the direct issuance of common stock and the grant of incentive and non-incentive stock options. As of March 31, 2016, no shares or options had been granted under the 2015 plan. Incentive Stock Options: The Company did not grant any stock options during the nine months ended March 31, 2015. The following assumptions were used for the nine months ended March 31, 2016: Nine Months Ended March 31, 2016 Expected volatility 142.05 % Expected dividend yield - Risk-free interest rates 1.19 % Expected term (in years) 3.0 to 5.0 The computation of expected volatility during the nine months ended March 31, 2016 was based on the historical volatility. Historical volatility was calculated from historical data for the time approximately equal to the expected term of the option award starting from the grant date. The risk-free interest rate assumption is based upon the U.S. Treasury yield curve in effect at the time of grant for the period corresponding with the expected life of the option. A summary of the activity of the Company’s stock options for the nine months ended March 31, 2016 is presented below: Weighted Weighted Weighted Average Average Average Number of Remaining Optioned Aggregate Exercise Optioned Contractual Grant Date Intrinsic Price Shares Term in Years Fair Value Value Balance as of June 30, 2015 0.07 67,737,748 0.10 $ 8,357,574 Expired - - - Granted 0.16 5,500,000 0.14 Exercised 0.06 (3,325,000 ) 0.06 Cancelled 0.09 (5,287,500 ) 0.16 Balance as of March 31, 2016 $ 0.07 64,625,248 4.56 $ 0.11 $ 2,431,596 Vested and exercisable as of March 31, 2016 $ 0.06 57,375,248 3.76 $ 0.10 $ 2,686,596 Outstanding options at March 31, 2016 expire during the period March 2017 to November 2025 and have exercise prices ranging from $0.03 to $0.17. Compensation expense associated with stock options for the three months ended March 31, 2016 and 2015 was $98,316 and $0, respectively, and $1,439,221 and $0 for the nine months ended March 31, 2016 and 2015, respectively, and was included in general and administrative expenses in the consolidated statements of operations. At March 31, 2016, the Company had 7,250,000 shares of nonvested stock option awards. The total cost of nonvested stock option awards which the Company had not yet recognized was $690,982 at March 31, 2016. Such amounts are expected to be recognized over a period of 2.75 years. Restricted Stock: Number of Weighted Nonvested Average Restricted Grant Date Share Awards Fair Value Nonvested restricted shares outstanding at June 30, 2015 1,500,000 $ 0.42 Granted 250,000 0.14 Vested (750,000 ) 0.33 Forfeited - - Nonvested restricted shares outstanding at March 31, 2016 1,000,000 $ 0.42 Compensation expense associated with restricted stock for the three months ended March 31, 2016 and 2015 was $52,356 and $51,781, respectively, and $193,219 and $149,014 for the nine months ended March 31, 2016 and 2015, respectively, and was included in general and administrative expenses in the consolidated statements of operations. The total cost of nonvested stock awards which the Company had not yet recognized was $270,411 at March 31, 2016. This amount is expected to be recognized over a period of 1.5 years. Agreements with Officers and Employees:

Loss Per Share

Loss Per Share	9 Months Ended
	Mar. 31, 2016
LOSS PER COMMON SHARE
Loss Per Share	NOTE 9 – LOSS PER SHARE The Company follows ASC 260, “Earnings Per Share”, The following table sets forth the computation of basic and diluted loss per share: Three Months Ended Nine Months Ended March 31, March 31, 2015 2015 2016 (Restated) 2016 (Restated) (unaudited) (unaudited) Net loss $ (752,360 ) $ (1,132,669 ) $ (4,138,967 ) $ (980,183 ) Weighted average common shares outstanding: Basic and diluted 322,675,999 281,526,245 316,418,240 269,903,313 Basic and diluted loss per share $ (0.00 ) $ (0.00 ) $ (0.01 ) $ (0.00 ) For the three and nine months ended March 31, 2016 and 2015, 35,466,779 and 46,931,832 stock warrants, respectively, were excluded from diluted earnings per share because they are considered anti-dilutive. For the three and nine months ended March 31, 2016 and 2015, 64,625,248 and 51,437,748 stock options, respectively, were excluded from diluted earnings per share because they are considered anti-dilutive.

Revenue

Revenue	9 Months Ended
	Mar. 31, 2016
Deferred Revenue Disclosure [Abstract]
Revenue	NOTE 10 – REVENUE During the three months ended March 31, 2016, the Company recognized $225,000 revenue. The revenue is a result of the Company entering into a funded product development agreement (the “Agreement”) with leading global film manufacturer, Nitto Denko Corporation, in September 2015. The $225,000 represents full payment pursuant to the Agreement and was initially classified as deferred revenue. The Company worked with Nitto Denko Corporation to develop quantum dot material, however the Agreement did not require specific deliverables by the Company. The Agreement did place certain restrictions on the Company’s ability to communicate with a limited number of specifically named businesses during the four month term of the agreement. Management does not believe the restrictions had a material negative affect on the Company’s business prospects.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 11 - COMMITMENTS AND CONTINGENCIES Agreement with Rice University On August 20, 2008, Solterra entered into a License Agreement with Rice University, which was amended and restated on September 26, 2011; also on September 26, 2011, QMC entered into a new License Agreement with Rice (collectively the “Rice License Agreements”). On August 21, 2013, QMC and Solterra each entered into amended license agreements with Rice University. QMC and Solterra entered into second amended license agreements with Rice University on March 15 and 24, 2016, respectively. The Rice License Agreements, as amended, require the payment of certain patent fees to Rice and for QMC and Solterra to meet certain milestones by specific dates. Pursuant to the Solterra Rice License Agreement, as amended, Rice is entitled to receive, during the term, certain royalties of adjusted gross sales (as defined therein) ranging from 2% to 4% for photovoltaic cells and 7.5% of adjusted gross sales for QDs sold in electronic and medical applications. Additionally, minimum royalties payable under the Solterra Rice License Agreement include $100,000 due January 1, 2017, $356,250 due January 1, 2018, $1,453,500 due January 1, 2019, $3,153,600 due January 1, 2020 and each January 1 of every year thereafter, subject to adjustments for changes in the consumer pricing index. Pursuant to the QMC Rice License Agreement, as amended, Rice is entitled to receive, during the term, a royalty of 7.5% of adjusted gross sales for QDs sold in electronic and medical applications. Additionally, minimum royalties payable under the QMC Rice License Agreement include $117,000 due January 1, 2017, $292,500 due January 1, 2018, $585,000 due January 1, 2019 and each January 1 of every year thereafter, subject to adjustments for changes in the consumer pricing index. The Rice License Agreements and subsequent amendments have been filed on Form 8-K and are incorporated by reference herein. Agreement with University of Arizona Solterra entered into an exclusive Patent License Agreement with the University of Arizona (“UA”) in July 2009. Pursuant to UA License Agreement, as amended, Solterra is obligated to pay minimum annual royalties of $50,000 by December 31, 2015, $125,000 by June 30, 2016 and $200,000 on each June 30th thereafter, subject to adjustments for increases in the consumer price index. As of the date of this Form 10-Q, the Company is working with UA to amend the license agreement to extend the due date of the $50,000 minimum royalty payment that was due December 31, 2015. Royalties based on net sales are 2% of net sales of licensed products for non-display electronic component applications and 2.5% of net sales of licensed products for printed electronic displays. The UA License Agreements and subsequent amendments have been filed on Form 8-K and are incorporated by reference herein. Agreement with Texas State University The Company entered into a Service Agreement with Texas State University (“TSU”) by which the Company occupies certain office and lab space at TSU’s STAR Park (Science Technology and Advanced Research) Facility. The agreement is month-to-month and can be terminated with 30-days written notice of either party.

Income Tax

Income Tax	9 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax	NOTE 12 – INCOME TAX The Company follows ASC 740 “Income Taxes” The Company assesses the likelihood that deferred tax assets will be recovered from the existing deferred tax liabilities or future taxable income. To the extent the Company believes that recovery will not meet the more likely than not threshold, it establishes a valuation allowance. The Company has recorded valuation allowances in the U.S. for its net deferred tax assets since management believes it is more likely than not that these assets will not be realized because future taxable income necessary to utilize these losses cannot be established or projected. The effective income tax rate for the three and nine months ended March 31, 2016 and 2015 was 0%. The Company’s effective income tax rate differs from the federal statutory rate primarily due to non-deductible expenses and valuation allowances. As a result of stock compensation expense incurred during the nine months ended March 31, 2016, the Company has increased deferred tax assets by approximately $660,000 with a corresponding increase to the valuation allowance.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Mar. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	NOTE 13 – SUPPLEMENTAL CASH FLOW INFORMATION The following is supplemental cash flow information: Nine Months Ended March 31, 2015 2016 (Restated) (unaudited) Cash paid for interest $ 20,055 $ 7,149 Cash paid for income taxes $ — $ — The following is supplemental disclosure of non-cash investing and financing activities: Nine Months Ended March 31, 2015 2016 (Restated) (unaudited) Conversion of debentures into shares of common stock $ — $ 1,475,000 Allocated value of warrants issued with convertible debentures $ — $ 551,179 Stock warrants issued for conversion of accrued salaries $ 409,667 $ — Prepaid expense paid in shares of common stock $ 131,655 $ 282,500 Financing of prepaid insurance $ 20,024 $ —

Transactions with Affiliated Pa

Transactions with Affiliated Party	9 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Transactions with Affiliated Party	NOTE 14 – TRANSACTIONS WITH AFFILIATED PARTY During the nine months ended March 31, 2016, the Company’s former CFO surrendered 638,300 shares of common stock and options to purchase an additional 987,500 shares in exchange for the cancellation of indebtedness to the Company aggregating $79,000. As a result of this surrender, the Company recorded a gain of $174,568 which is presented in the consolidated statements of operations as Gain on Settlement. During the three months ended March 31, 2016, The Company’s current CFO and two of the Company’s directors invested $15,000, $10,000, and $25,000 respectively in the private placement described below in Note 16.

Recently issued accounting stan

Recently issued accounting standards	9 Months Ended
	Mar. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Recently issued accounting standards	NOTE 15 – RECENTLY ISSUED ACCOUNTING STANDARDS In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers Revenue from Contracts with Customers: Deferral of the Effective Date, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing. In March 2016, the FASB issued ASU 2016-09, Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting. In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes. In February 2016, the FASB issued ASU 2016-02, Leases,which updates guidance on accounting for leases. The update requires that a lessee recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Similar to current guidance, the update continues to differentiate between finance leases and operating leases; however, this distinction now primarily relates to differences in the manner of expense recognition over time and in the classification of lease payments in the statement of cash flows. The standards update is effective for interim and annual periods after December 15, 2018 with early adoption permitted. Entities are required to use a modified retrospective adoption, with certain relief provisions, for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements when adopted. The Company is in the process of evaluating the impact, if any, of the adoption of this guidance on its consolidated financial statements.

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	NOTE 16 - SUBSEQUENT EVENTS The Company’s previously announced private placement of up to 2,000 Units raised approximately $1.5 million in net proceeds. Each Unit consists of a $1,000 Unsecured Convertible Promissory Note (each, a “Note”) and a warrant to purchase 4,166 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $0.15 per share (each, a “Warrant”) over a period of five years. The Notes which were issued at face value have a maturity of two years from the date of issuance, bear interest at the rate of 8% per annum (the interest rate was previously reported as 6% on the Form 8-K filed on March 31, 2016) and are convertible into shares of Common Stock at $0.12 per-share, subject to normal and customary adjustments including (a) any subdivisions, combinations and classifications of the Common Stock; or (b) any payment, issuance or distribution by the Company to its stockholders of (i) a stock dividend, (ii) debt securities of the Company, or (iii) assets (other than cash dividends payable out of earnings or surplus in the ordinary course of business). The conversion price also is subject to a full ratchet adjustment upon the Company’s issuance of Common Stock, warrants, or rights to purchase Common Stock or securities convertible into Common Stock for a consideration per share which is less than the then applicable conversion price of the Notes excluding Common Stock and options issued to officers, directors, and employees of the Company, except for the exercise or conversion of existing convertible securities of the Company. The number of Warrants and exercise price is proportionately adjustable for events including subdivisions, combinations or consolidations, reclassifications, exchanges, mergers, and reorganizations. On April 8, 2016, the Company announced that current Director Daniel Carlson has assumed the role of Chairman, taking over from the Company’s CEO, Stephen A. Squires who remains a Director. On April 13, 2016, the Company issued 4,250,000 stock options to employees. The stock options have an exercise price of $0.12 and vest annually over three years.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying consolidated financial statements include the accounts of Quantum Materials Corp. and its wholly owned subsidiary, Solterra Renewable Technologies, Inc. (collectively referred to as the “Company”). The consolidated financial statements of the Company as of and for the three and nine months ended March 31, 2016 are unaudited and have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended June 30, 2015. The year-end balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S. In the opinion of management, the accompanying unaudited financial information includes all adjustments necessary for a fair presentation of the interim financial information. Operating results for the interim periods are not necessarily indicative of the results of any subsequent periods. Certain information in the footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted for the interim periods presented under the United States Securities and Exchange Commission (“SEC”) rules and regulations. As such, these interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended June 30, 2015. Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the classifications of the current year consolidated financial statements.
Nature of Operations	Nature of Operations The Company is a nanotechnology company specializing in the design, development, production and supply of quantum dots, including tetrapod quantum dots, a high performance variant of quantum dots, and highly uniform nanoparticles, using its patented automated continuous flow production process. Quantum dots and other nanoparticles are expected to be increasingly utilized in a range of applications in the life sciences, television and display, solid state lighting, solar energy, battery, security ink, and sensor sectors of the market. Key uncertainties and risks to the Company include, but are not limited to, if and how quickly various industries adopt and fully embrace quantum dot technology and technological changes, including those developed by our competitors, rendering our technology uncompetitive or obsolete.
Going Concern	Going Concern The Company recorded losses from continuing operations in the current period presented and has a history of losses. The ability of the Company to continue as a going concern is dependent upon its ability to reverse negative operating trends, obtain revenues from operations, raise additional capital, and/or obtain debt financing. In conjunction with anticipated revenue streams, management is currently negotiating equity and debt financing, the proceeds from which would be used to settle outstanding debts, to finance operations, and for general corporate purposes. However, there can be no assurance that the Company will be able to raise capital, obtain debt financing, or improve operating results sufficiently to continue as a going concern. The accompanying unaudited consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.
Restatement of Unaudited Quarterly Financial Data	Restatement of Unaudited Quarterly Financial Data The Company identified certain errors in the Company’s previously released financial information for the quarters ended December 31, 2014 and March 31, 2015. As a result of the identification of the issues, various accounting corrections to the previously reported financial information were recorded and reported on Form 10-K/A filed with the Securities and Exchange Commission on February 2, 2016 and are incorporated by reference herein.

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: March 31, 2016 June 30, 2015 (unaudited) Furniture and fixtures $ 1,625 $ 1,625 Computers and software 11,447 11,447 Machinery and equipment 874,041 826,582 887,113 839,654 Less: accumulated depreciation 127,468 63,615 Total property and equipment, net $ 759,645 $ 776,039

Licenses and Patents (Tables)

Licenses and Patents (Tables)	9 Months Ended
	Mar. 31, 2016
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Licenses and Patents	Licenses and patents consisted of the following: March 31, 2016 June 30, 2015 (unaudited) William Marsh Rice University $ 40,000 $ 40,000 University of Arizona 15,000 15,000 Bayer acquired patents 137,743 137,743 192,743 192,743 Less: accumulated amortization 65,618 36,707 Total licenses and patents, net $ 127,125 $ 156,036

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value of Convertible Debentures	The following table sets forth the fair value of the Company’s convertible debentures as of March 31, 2016 and June 30, 2015: March 31, 2016 June 30, 2015 (unaudited) Carrying Fair Carrying Fair Amount Value Amount Value Convertible debentures issued September 18, 2014 $ 25,050 $ 18,370 $ 25,050 $ 31,730 Convertible debentures issued January 15, 2015 $ 500,000 $ 916,667 $ 500,000 $ 1,583,333

Convertible Debentures (Tables)

Convertible Debentures (Tables)	9 Months Ended
	Mar. 31, 2016
Debt Disclosure [Abstract]
Schedule of Convertible Debentures	The following table sets forth activity associated with the convertible debentures: March 31, 2016 June 30, 2015 (unaudited) Convertible debentures issued November 4, 2008 $ - $ 500,000 Convertible debentures issued February 6, 2014 - 400,000 Convertible debentures issued September 18, 2014 25,050 500,050 Convertible debentures issued November 25, 2014 - 350,000 Convertible debentures issued January 15, 2015 500,000 500,000 525,050 2,250,050 Less: amount converted to shares - 1,725,000 Total convertible debentures outstanding 525,050 525,050 Less: unamortized discount 137,085 266,212 387,965 258,838 Less: current portion 362,915 - Total convertible debentures, net of current portion $ 25,050 $ 258,838

Equity Transaction (Tables)

Equity Transaction (Tables)	9 Months Ended
	Mar. 31, 2016
Equity [Abstract]
Summary of Activity of Company's Stock Warrants	A summary of activity of the Company’s stock warrants for the nine months ended March 31, 2016 is presented below: Weighted Weighted Average Weighted Average Remaining Average Exercise Number of Contractual Grant Date Price Warrants Term in Years Fair Value Balance as of June 30, 2015 $ 0.09 48,284,833 $ 0.13 Expired 0.07 (7,895,833 ) 0.08 Granted 0.06 9,048,508 0.13 Exercised 0.07 (13,554,062 ) 0.09 Cancelled 0.24 (416,667 ) 0.14 Balance as of March 31, 2016 $ 0.09 35,466,779 1.32 $ 0.15 Vested and exercisable as of March 31, 2016 $ 0.09 35,466,779 1.32 $ 0.15

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Valuation Assumptions Used to Estimate Fair Value of Stock Options	The following assumptions were used for the nine months ended March 31, 2016: Nine Months Ended March 31, 2016 Expected volatility 142.05 % Expected dividend yield - Risk-free interest rates 1.19 % Expected term (in years) 3.0 to 5.0
Summary of Award Activity Under Stock Option Plans	A summary of the activity of the Company’s stock options for the nine months ended March 31, 2016 is presented below: Weighted Weighted Weighted Average Average Average Number of Remaining Optioned Aggregate Exercise Optioned Contractual Grant Date Intrinsic Price Shares Term in Years Fair Value Value Balance as of June 30, 2015 0.07 67,737,748 0.10 $ 8,357,574 Expired - - - Granted 0.16 5,500,000 0.14 Exercised 0.06 (3,325,000 ) 0.06 Cancelled 0.09 (5,287,500 ) 0.16 Balance as of March 31, 2016 $ 0.07 64,625,248 4.56 $ 0.11 $ 2,431,596 Vested and exercisable as of March 31, 2016 $ 0.06 57,375,248 3.76 $ 0.10 $ 2,686,596
Summary of Award Activity Under Restricted Stock Plans	A summary of the activity of the Company’s restricted stock awards for the nine months ended March 31, 2016 is presented below: Number of Weighted Nonvested Average Restricted Grant Date Share Awards Fair Value Nonvested restricted shares outstanding at June 30, 2015 1,500,000 $ 0.42 Granted 250,000 0.14 Vested (750,000 ) 0.33 Forfeited - - Nonvested restricted shares outstanding at March 31, 2016 1,000,000 $ 0.42

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Mar. 31, 2016
LOSS PER COMMON SHARE
Schedule of Computation of Basic and Diluted Loss Per Share	The following table sets forth the computation of basic and diluted loss per share: Three Months Ended Nine Months Ended March 31, March 31, 2015 2015 2016 (Restated) 2016 (Restated) (unaudited) (unaudited) Net loss $ (752,360 ) $ (1,132,669 ) $ (4,138,967 ) $ (980,183 ) Weighted average common shares outstanding: Basic and diluted 322,675,999 281,526,245 316,418,240 269,903,313 Basic and diluted loss per share $ (0.00 ) $ (0.00 ) $ (0.01 ) $ (0.00 )

Supplemental Cash Flow Inform31

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Mar. 31, 2016
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following is supplemental cash flow information: Nine Months Ended March 31, 2015 2016 (Restated) (unaudited) Cash paid for interest $ 20,055 $ 7,149 Cash paid for income taxes $ — $ — The following is supplemental disclosure of non-cash investing and financing activities: Nine Months Ended March 31, 2015 2016 (Restated) (unaudited) Conversion of debentures into shares of common stock $ — $ 1,475,000 Allocated value of warrants issued with convertible debentures $ — $ 551,179 Stock warrants issued for conversion of accrued salaries $ 409,667 $ — Prepaid expense paid in shares of common stock $ 131,655 $ 282,500 Financing of prepaid insurance $ 20,024 $ —

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 21,853	$ 8,354	$ 63,853	$ 24,048

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Property and equipment gross	$ 887,113	$ 839,654
Less: accumulated depreciation	127,468	63,615
Total property and equipment, net	759,645	776,039
Furniture and Fixtures [Member]
Property and equipment gross	1,625	1,625
Computers and Software [Member]
Property and equipment gross	11,447	11,447
Machinery and Equipment [Member]
Property and equipment gross	$ 874,041	$ 826,582

Licenses and Patents (Details N

Licenses and Patents (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Finite-Lived Intangible Assets, Net [Abstract]
Amortization expense	$ 9,637	$ 9,637	$ 28,911	$ 24,320

Licenses and Patents - Schedule

Licenses and Patents - Schedule of Licenses and Patents (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Licenses and patents, gross	$ 192,743	$ 192,743
Less: accumulated amortization	65,618	36,707
Total licenses and patents, net	127,125	156,036
William Marsh Rice University [Member]
Licenses and patents, gross	40,000	40,000
University of Arizona [Member]
Licenses and patents, gross	15,000	15,000
Bayer Acquired Patents [Member]
Licenses and patents, gross	$ 137,743	$ 137,743

Fair Value of Financial Instr36

Fair Value of Financial Instruments (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Recognized a gain		$ 0		$ 1,871,337

Fair Value of Financial Instr37

Fair Value of Financial Instruments - Schedule of Fair Value of Convertible Debentures (Details) - Level 2 [Member] - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Convertible Debentures Issued September 18, 2014 [Member] | Carrying Value [Member]
Convertible debentures	$ 25,050	$ 25,050
Convertible Debentures Issued September 18, 2014 [Member] | Fair Value [Member]
Convertible debentures	18,370	31,730
Convertible Debentures Issued January 15, 2015 [Member] | Carrying Value [Member]
Convertible debentures	500,000	500,000
Convertible Debentures Issued January 15, 2015 [Member] | Fair Value [Member]
Convertible debentures	$ 916,667	$ 1,583,333

Convertible Debentures (Details

Convertible Debentures (Details Narrative)	Jan. 15, 2015USD ($)NonaffiliatedParties$ / sharesshares	Nov. 25, 2014USD ($)Fundings$ / shares	Sep. 16, 2014USD ($)NonaffiliatedParties$ / shares	Feb. 06, 2014USD ($)NonaffiliatedParties$ / sharesshares	Nov. 04, 2008USD ($)NonaffiliatedParties$ / sharesshares	Mar. 31, 2016USD ($)	Feb. 29, 2016USD ($)	Apr. 30, 2015USD ($)shares	Jan. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Oct. 31, 2014USD ($)shares	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Apr. 30, 2015USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Jun. 30, 2014USD ($)$ / sharesshares	Nov. 30, 2015$ / shares	Jun. 30, 2015USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of convertible debenture																$ 1,200,050
Debt instrument principal amount						$ 525,050						$ 525,050			$ 525,050				$ 2,250,050
Warrants exercise price per share | $ / shares																		$ 0.06
Debenture conversion amount																1,475,000
Accretion of debt discount												43,903	$ 92,323		$ 129,127	310,733
Private Individual [Member]
Debt Instrument [Line Items]
Debt instruments maturity date							May 5, 2016
Debt interest rate							0.50%
Unsecured promissory							$ 150,000
November 2008 Convertible Debt [Member]
Debt Instrument [Line Items]
Proceeds from issuance of convertible debenture					$ 1,500,000
Shares issued in exchange for debentures					3,525,000
Debt instrument principal amount					$ 1,500,000
Debt instruments maturity date					Nov. 4, 2014
Aggregate number of warrants issued | shares					2,000,000
Debt term					3 years
Debt interest rate					8.00%
Number of non-affiliated parties | NonaffiliatedParties					3
Warrants exercise price per share | $ / shares					$ 0.10
Debenture, conversion price | $ / shares					$ 0.06
Interest expense												0	0		0	21,805
Convertible debenture fair value						0						0			0				0
November 2008 Convertible Debt [Member] | Convertible Debt One [Member]
Debt Instrument [Line Items]
Debenture, conversion price | $ / shares																	$ 0.06
Debenture conversion amount																	$ 1,000,000
Shares issued for conversion of debentures | shares																	16,666,667
November 2008 Convertible Debt [Member] | Convertible Debt Two [Member]
Debt Instrument [Line Items]
Debenture, conversion price | $ / shares																	$ 0.06
Debenture conversion amount																	$ 500,000
Shares issued for conversion of debentures | shares																	8,333,333
February 2014 Convertible Debt [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				$ 400,000
Debt instruments maturity date				Jan. 31, 2016
Aggregate number of warrants issued | shares				5,000,000
Debt term				2 years
Debt interest rate				8.00%
Number of non-affiliated parties | NonaffiliatedParties				2
Warrants exercise price per share | $ / shares				$ 0.06
Debenture, conversion price | $ / shares				$ 0.04
Debenture conversion amount									$ 400,000
Shares issued for conversion of debentures | shares									10,000,000
Interest expense												0	18,762		0	18,762
Convertible debenture fair value						0						0			0				0
Debt instrument, preferential right to fund				$ 650,000
Allocated value of warrants related to debenture				$ 95,603
Accretion of debt discount												0	51,785		0	51,785
September 2014 Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt instrument principal amount			$ 500,050
Debt term			5 years
Debt interest rate			6.00%
Number of non-affiliated parties | NonaffiliatedParties			5
Debenture, conversion price | $ / shares			$ 0.15
Debenture conversion amount										$ 125,000	$ 350,000
Shares issued for conversion of debentures | shares										833,334	2,333,333
Interest expense												380	0		1,148	4,073
Convertible debenture fair value						25,050						25,050			25,050				25,050
Debt instrument, preferential right to fund			$ 203,074
Accretion of debt discount												0	0		0	203,074
Maturity date description			September 16, 2019 and October 30, 2019
Percentage of strike price per share | $ / shares			$ 0.30
Beneficial conversion feature												0	0		0	230,309
November 2014 Convertible Debenture [Member]
Debt Instrument [Line Items]
Proceeds from issuance of convertible debenture		$ 500,000												$ 350,000
Debt instruments maturity date		Nov. 25, 2019
Debt term		5 years
Debt interest rate		6.00%
Debenture conversion amount								$ 250,000	$ 100,000
Shares issued for conversion of debentures | shares								2,250,000	666,667
Convertible debenture fair value						$ 0						0			0				$ 0
Beneficial conversion feature												0	45,833		0	45,833
Number of fundings | Fundings		5
November 2014 Convertible Debenture [Member] | First Three Fundings [Member]
Debt Instrument [Line Items]
Debenture, conversion price | $ / shares		$ 0.15
Authorized borrowing		$ 50,000
November 2014 Convertible Debenture [Member] | Fourth Fundings [Member]
Debt Instrument [Line Items]
Debenture, conversion price | $ / shares		$ 0.12
Authorized borrowing		$ 50,000
November 2014 Convertible Debenture [Member] | Fifth Fundings [Member]
Debt Instrument [Line Items]
Debenture, conversion price | $ / shares		$ 0.10
Authorized borrowing		$ 150,000
January 2015 Convertible Debenture [Member]
Debt Instrument [Line Items]
Proceeds from issuance of convertible debenture	$ 500,000
Debt instruments maturity date	Jan. 15, 2017
Aggregate number of warrants issued | shares	6,250,000
Debt interest rate	8.00%
Number of non-affiliated parties | NonaffiliatedParties	2
Warrants exercise price per share | $ / shares	$ 0.06
Debenture, conversion price | $ / shares	$ 0.06
Interest expense												9,973	0		30,137	0
Allocated value of warrants related to debenture	$ 348,105
Accretion of debt discount												43,903	40,538		129,127	40,538
Beneficial conversion feature												$ 0	$ 151,895		$ 0	$ 151,895
Negotiable Promissory Note [Member]
Debt Instrument [Line Items]
Debt instruments maturity date						Nov. 11, 2016
Debt interest rate						4.87%						4.87%			4.87%
Notes payable						$ 20,024						$ 20,024			$ 20,024
Proceeds from notes payable						$ 20,024

Convertible Debentures - Schedu

Convertible Debentures - Schedule of Convertible Debentures (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Debt Instrument [Line Items]
Convertible debenture	$ 525,050	$ 2,250,050
Less: amount converted to shares		1,725,000
Total convertible debentures outstanding	$ 525,050	525,050
Less: unamortized discount	137,085	266,212
Total convertible debt	387,965	$ 258,838
Less: current portion	362,915
Total convertible debentures, net of current portion	$ 25,050	$ 258,838
Convertible Debentures Issued November 4, 2008 [Member]
Debt Instrument [Line Items]
Convertible debenture		500,000
Convertible Debentures Issued February 6, 2014 [Member]
Debt Instrument [Line Items]
Convertible debenture		400,000
Convertible Debentures Issued September 18, 2014 [Member]
Debt Instrument [Line Items]
Convertible debenture	$ 25,050	500,050
Convertible Debentures Issued November 25, 2014 [Member]
Debt Instrument [Line Items]
Convertible debenture		350,000
Convertible Debentures Issued January 15, 2015 [Member]
Debt Instrument [Line Items]
Convertible debenture	$ 500,000	$ 500,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 31, 2016	Feb. 29, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Negotiable Promissory Note [Member]
Debt interest rate	4.87%		4.87%		4.87%
Debt instruments maturity date	Nov. 11, 2016
Notes payable	$ 20,024		$ 20,024		$ 20,024
Proceeds from notes payable	$ 20,024
Private Individual [Member]
Unsecured promissory		$ 150,000
Debt interest rate		0.50%
Debt instruments maturity date		May 5, 2016
Interest expense			$ 100	$ 0	$ 100	$ 0

Equity Transactions (Details Na

Equity Transactions (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Nov. 30, 2015	Mar. 31, 2016
Proceeds from issuance of common stock		$ 100,000
Proceeds from exercise of options and warrants		360,500
Forgiveness of a liability		$ 39,177
Number of options exercised in noncash transaction, shares		3,325,000
Common stock issued for services		$ 290,000
Accrued salaries and wages converted into common stock and stock options	$ 409,667
Common stock issued in exchange for accrued salaries, shares	6,827,778
Warrant exercisable term	2 years
Warrants exercise price per share	$ 0.06
Fair value of warrants	$ 821,979
Variance recognized due to issue of warrants	$ 412,312
Minimum [Member]
Warrants exercise price per share		$ 0.04
Maximum [Member]
Warrants exercise price per share		$ 0.30
Consultant [Member]
Common stock issued for services, shares		100,000
Common stock issued for services		$ 10,000
Common Stock [Member]
Common stock shares issued for cash		1,000,000
Stock issued for exercise of options and warrants, shares		12,279,211
Number of warrants exercised in noncash transaction, shares		6,802,634
Number of shares issued upon exercise of options in noncash transactions, shares		2,146,629
Number of shares of stock issued for warrants exercised in noncash transaction, shares		3,381,154
Common stock issued for services, shares		2,900,000
Common stock issued for services		$ 2,900
Number of shares cancelled during period		638,300
Common Stock [Member] | Consultant [Member]
Common stock issued for services, shares		2,800,000
Common stock issued for services		$ 280,000

Equity Transactions - Summary o

Equity Transactions - Summary of Activity of Company's Stock Warrants (Details) - Warrant [Member]	9 Months Ended
	Mar. 31, 2016$ / sharesshares
Weighted Average Exercise Price Beginning Balance	$ 0.09
Weighted Average Exercise Price Expired	0.07
Weighted Average Exercise Price Granted	0.06
Weighted Average Exercise Price Exercised	0.07
Weighted Average Exercise Price Cancelled	0.24
Weighted Average Exercise Price Ending Balance	0.09
Weighted Average Exercise Price Vested and exercisable	$ 0.09
Number of Warrants Beginning Balance | shares	48,284,833
Number of Warrants Expired | shares	(7,895,833)
Number of Warrants Granted | shares	9,048,508
Number of Warrants Exercised	$ (13,554,062)
Number of Warrants Cancelled | shares	(416,667)
Number of Warrants Ending Balance | shares	35,466,779
Number of Warrants Vested and exercisable | shares	35,466,779
Weighted Average Remaining Contractual Term in Years	1 year 3 months 26 days
Weighted Average Remaining Contractual Term in Years Vested and exercisable	1 year 3 months 26 days
Weighted Average Grant Date Fair Value Beginning Balance	$ 0.13
Weighted Average Grant Date Fair Value Expired	0.08
Weighted Average Grant Date Fair Value Granted	0.13
Weighted Average Grant Date Fair Value Exercised	0.09
Weighted Average Grant Date Fair Value Cancelled	0.14
Weighted Average Grant Date Fair Value Ending Balance	0.15
Weighted Average Grant Date Fair Value Vested and exercisable	$ 0.15

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative)

1 Months Ended

3 Months Ended

9 Months Ended

Mar. 31, 2012shares

Mar. 31, 2016USD ($)$ / sharesshares

Mar. 31, 2015USD ($)

Mar. 31, 2017

Mar. 31, 2016USD ($)Options$ / sharesshares

Mar. 31, 2015USD ($)

Feb. 17, 2016shares

Sep. 30, 2015shares

Mar. 31, 2013shares

Jan. 31, 2013shares

Jan. 31, 2010shares

Oct. 31, 2009shares

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options granted, shares

3,500,000

Options term

5 years

Compensation expense | $

$ 98,316

$ 0

$ 1,439,221

$ 0

Nonvested stock option awards, shares

7,250,000

7,250,000

Cost of nonvested stock option awards not yet recognized | $

$ 690,982

$ 690,982

Period of nonvested stock option awards not yet recognized for recognition

2 years 9 months

Stock Options [Member] | Officers And Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options cancelled, shares

4,300,000

4,300,000

Number of shares restricted for exercise under stock option plan and no common stock reserved

53,679,414

53,679,414

57,979,414

Number of officers returning options to the company | Options

1

Stock Options [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option exercise price per share | $ / shares

$ 0.03

$ 0.03

Option expiration year

2017-03

Stock Options [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock option exercise price per share | $ / shares

$ 0.17

$ 0.17

Option expiration year

2025-11

Stock Options [Member] | Stock Option Plan Authorized 2009 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock authorized, shares

10,000,000

7,500,000

Options granted, shares

9,200,000

9,200,000

Options cancelled, shares

250,000

250,000

Stock Options [Member] | Stock Option Plan Authorized 2009 [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options term

5 years

Stock Options [Member] | Stock Option Plan Authorized 2009 [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options term

10 years

Stock Options [Member] | Stock Option Plan Authorized 2013 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock authorized, shares

60,000,000

20,000,000

Options granted, shares

68,203,473

68,203,473

Options cancelled, shares

12,703,225

12,703,225

Options exercised, shares

3,325,000

3,325,000

Stock Options [Member] | Stock Option Plan Authorized 2013 [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options term

5 years

Stock Options [Member] | Stock Option Plan Authorized 2013 [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options term

10 years

Stock Options [Member] | Employee Benefit And Consulting Services Compensation Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock authorized, shares

15,000,000

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation expense | $

$ 51,781

$ 52,356

$ 193,219

$ 149,014

Cost of nonvested stock option awards not yet recognized | $

$ 270,411

$ 270,411

Period of nonvested stock option awards not yet recognized for recognition

1 year 6 months

Option vesting period

3 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Valuation Assumptions Used to Estimate Fair Value of Stock Options (Details)	9 Months Ended
	Mar. 31, 2016
Expected volatility	142.05%
Expected dividend yield
Risk-free interest rates	1.19%
Minimum [Member]
Expected term	3 years
Maximum [Member]
Expected term	5 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Award Activity Under Stock Option Plans (Details)	9 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted Average Exercise Price Balance	$ 0.07
Weighted Average Exercise Price Granted	0.16
Weighted Average Exercise Price Exercised	0.06
Weighted Average Exercise Price Cancelled	0.09
Weighted Average Exercise Price Balance	0.07
Weighted Average Exercise Price Vested and exercisable	$ 0.06
Number of Optioned Shares Balance | shares	67,737,748
Number of Optioned Shares Granted | shares	5,500,000
Number of Optioned Shares Exercised | shares	(3,325,000)
Number of Optioned Shares Cancelled | shares	(5,287,500)
Number of Optioned Shares Balance | shares	64,625,248
Number of Optioned Shares Vested and exercisable | shares	57,375,248
Weighted Average Remaining Contractual Term in Years Balance	4 years 6 months 22 days
Weighted Average Remaining Contractual Term in Years Vested and exercisable	3 years 9 months 4 days
Weighted Average Optioned Grant Date Fair Value Balance	$ 0.10
Weighted Average Optioned Grant Date Fair Value Granted	0.14
Weighted Average Optioned Grant Date Fair Value Exercised	0.06
Weighted Average Optioned Grant Date Fair Value Cancelled	0.16
Weighted Average Optioned Grant Date Fair Value Balance	0.11
Weighted Average Optioned Grant Date Fair Value Vested and exercisable	$ 0.10
Aggregate Intrinsic Value Aggregate intrinsic value Balance | $	$ 8,357,574
Aggregate Intrinsic Value Aggregate intrinsic value Balance | $	2,431,596
Aggregate Intrinsic Value Vested and exercisable | $	$ 2,686,596

Stock-Based Compensation - Su46

Stock-Based Compensation - Summary of Award Activity Under Restricted Stock Plans (Details) - Restricted Stock [Member]	9 Months Ended
	Mar. 31, 2016$ / sharesshares
Number of Nonvested Restricted Shares Awards, Beginning Balance | shares	1,500,000
Number of Nonvested Restricted Shares Awards, Granted | shares	250,000
Number of Nonvested Restricted Shares Awards, Vested | shares	(750,000)
Number of Nonvested Restricted Shares Awards, Forfeited | shares
Number of Nonvested Restricted Shares Awards, Ending Balance | shares	1,000,000
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 0.42
Weighted Average Grant Date Fair Value, Granted | $ / shares	0.14
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 0.33
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 0.42

Loss Per Share (Details Narrati

Loss Per Share (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock excluded from diluted EPS	35,466,779	46,931,832	35,466,779	46,931,832
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock excluded from diluted EPS	64,625,248	51,437,748	64,625,248	51,437,748

Loss Per Share - Schedule of Co

Loss Per Share - Schedule of Computation of Basic and Diluted Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
LOSS PER COMMON SHARE
Net loss	$ (752,360)	$ (1,132,669)	$ (4,138,967)	$ (980,183)
Weighted average common shares outstanding: Basic and diluted	322,675,999	281,526,245	316,418,240	269,903,313
Basic and diluted loss per share	$ 0	$ 0	$ (0.01)	$ 0

Revenue (Details Narrative)

Revenue (Details Narrative)	Mar. 31, 2016USD ($)
Deferred Revenue Disclosure [Abstract]
Deferred revenue	$ 225,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	9 Months Ended
	Mar. 31, 2016USD ($)
William Marsh Rice University [Member] | Licensing Agreements Entered Into During August2013 [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties payable due in first installment period	$ 117,000
Royalties payable due in second installment period	292,500
Royalties, future minimum payments due on each January 1st thereafter	$ 585,000
William Marsh Rice University [Member] | Quantum Dots [Member] | Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of adjusted gross sales	7.50%
Texas State University [Member] | Service Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Period of termination notice for the Memorandum of Understanding	30 days
Solterra Renewable Technologies Inc [Member] | William Marsh Rice University [Member] | Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties payable due in first installment period	$ 100,000
Royalties payable due in second installment period	356,250
Royalties payable due in third installment period	1,453,500
Royalties, future minimum payments due on each January 1st thereafter	$ 3,153,600
Solterra Renewable Technologies Inc [Member] | William Marsh Rice University [Member] | Photovoltaic Cells [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of adjusted gross sales	2.00%
Solterra Renewable Technologies Inc [Member] | William Marsh Rice University [Member] | Photovoltaic Cells [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of adjusted gross sales	4.00%
Solterra Renewable Technologies Inc [Member] | William Marsh Rice University [Member] | Quantum Dots [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of adjusted gross sales	7.50%
Solterra Renewable Technologies Inc [Member] | University Of Arizona [Member] | Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties payable due in first installment period	$ 50,000
Royalties payable due in second installment period	125,000
Royalties, future minimum payments due on each January 1st thereafter	$ 200,000
Solterra Renewable Technologies Inc [Member] | University Of Arizona [Member] | Non Display Electronic Component Applications [Member] | Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of adjusted gross sales	2.00%
Solterra Renewable Technologies Inc [Member] | University Of Arizona [Member] | Printed Electronic Displays [Member] | Licensing Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Percentage of adjusted gross sales	2.50%

Income Tax (Details Narrative)

Income Tax (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Tax at U.S. federal statutory rate	0.00%	0.00%	0.00%	0.00%
Increased deferred tax assets	$ 626,000		$ 626,000
Increase in valuation allowance			$ 660,000

Supplemental Cash Flow Inform52

Supplemental Cash Flow Information - Supplemental Cash Flow Information (Details) - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest	$ 20,055	$ 7,149
Cash paid for income taxes
Conversion of debentures into shares of common stock		$ 1,475,000
Allocated value of warrants issued with convertible debentures		$ 551,179
Stock warrants issued for conversion of accrued salaries	$ 409,667
Prepaid expense paid in shares of common stock	131,655	$ 282,500
Financing of prepaid insurance	$ 20,024

Transactions with Affiliated 53

Transactions with Affiliated Party (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Related Party Transaction [Line Items]
Gain on settlement			$ 174,568	$ 546,129
Former Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Number of shares of common stock surrendered			638,300
Number of common stock options surrendered by related party			987,500
Cancellation of indebtedness of related party			$ 79,000
Gain on settlement			174,568
CFO [Member]
Related Party Transaction [Line Items]
Investment in private placement	$ 15,000		15,000
Director One [Member]
Related Party Transaction [Line Items]
Investment in private placement	10,000		10,000
Director Two [Member]
Related Party Transaction [Line Items]
Investment in private placement	$ 25,000		$ 25,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Apr. 13, 2016	Mar. 31, 2016	Apr. 30, 2016	Mar. 31, 2016	Jun. 30, 2015
Common stock, par value		$ 0.001		$ 0.001	$ 0.001
Number of option issued during period				3,325,000
Subsequent Event [Member]
Number of maximum units to private placement		2,000
Proceeds from issuance of private placement		$ 1,500,000
Subsequent Event [Member] | Employees [Member]
Number of option issued during period	4,250,000
Stock option exercise price per share	$ 0.12
Option vesting period	3 years
Subsequent Event [Member] | Each Unit Consists Of Following [Member]
Unsecured Convertible Promissory Note			$ 1,000
Warrant issued to purchase number of common stock			4,166
Common stock, par value			$ 0.001
Warrant purchase price per share			$ 0.15
Private placement offering term			5 years
Debt instrument, maturity term			2 years
Debt instrument, interest rate		6.00%	8.00%	6.00%
Note converted into common stock, conversion price per share			$ 0.12